Trial Profile

A Phase 1 single-ascending dose (SAD) component and a multiple-ascending dose (MAD) component trial of APG777 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG 777 (Primary)
Indications Asthma; Atopic dermatitis; Inflammation
Focus Adverse reactions; First in man

Most Recent Events

02 Dec 2024 Results presented in the Apogee Therapeutics Media Release.
24 Oct 2024 According to an Apogee Therapeutics media release, company announced updated positive results from this trial and will poster presentation at the American College of Allergy, Asthma & Immunologys (ACAAI) 2024 Annual Scientific Meeting held in Boston from October 24-28, 2024.
24 Oct 2024 According to an Apogee Therapeutics media release, company expects to report 16-week topline data from Part A of the trial in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com